Abstract
We thank Lim and colleagues [1] for questioning how best to modulate complement pathway to improve outcomes of patients with COVID-19. In our study, we found that in patients with severe COVID-19, eculizumab treatment associated reduction in soluble C5b-9 paralleled the reduction of the concentrations of circulating proinflammatory cytokines and arterial lactate [2]. To explore the effects of eculizumab treatment on the second limb of the terminal complement pathway, we retrospectively measured C5a concentrations at baseline, day-1 and day-7 in 44/80 patients (14/45 and 30/35 in the eculizumab free and treated, respectively).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.